Enlivex Therapeutics Ltd.
NASDAQ:ENLVBiotechnology
+$0.19 today
- Market cap
- $71.70M
- Beta
- 1.52
- P/E (TTM)
- 0.0
- EPS (TTM)
- $407.81
Volume 0.06M
Average 0.44M
Returns on capital
Enlivex Therapeutics Ltd. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
63.9%
avg -71.5%
ROIC
-0.5%
avg -73.4%
ROA
53.1%
avg -59.3%
Analysis
ROE is currently the strongest return metric at 63.9% versus its period average of -71.5%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Shai Novik | Executive Chairman | USD 528K | 60 | — | — |
Oren Hershkovitz | Chief Executive Officer | USD 273.6K | 49 | 172.85K | 1.03% |
Dror Mevorach | Founder and Scientific Advisor | USD 180K | 70 | — | — |
Shachar Shlosberger | Chief Financial Officer | USD 126K | 49 | 139.31K | 0.83% |
Veronique Amor-Baroukh | Senior Director of Operations | — | — | — | — |
Einat Galamidi | Chief Medical Officer | — | 52 | 156.30K | 0.93% |
Sigal Arad | Director of Human Resources | — | — | — | — |
Compensation is shown in the reported currency; data updated Jul 9, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 18, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A0 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Enlivex Therapeutics Ltd. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ENLV's management, answered from reported figures.
Who manages ENLV?
Enlivex Therapeutics Ltd. (ENLV) lists 7 active executives. The top listed executive is Veronique Amor-Baroukh, Senior Director of Operations.
Are ENLV insiders buying or selling?
Recent insider activity shows net selling of $126,764.20.
Continue the stock analysis
Jump to another research area for this company.